Clinical Trial Search

Primary: Hamilton Depression Rating Scale (HAM-D) — 22.0; 21.8; 22.0; 8.8 units on a scale

Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05

Primary: Proportion of Patients Who Are Progression-free (CR, PR and Stable Disease) — 4 participants

Primary: Number of Subjects Withdrawn Due to An Adverse Event (AE) From Visit 1 (Day 1) Through End of Study — 3 subjects

Primary: Percentage of Participants That Are Relapse-free 5 Years After Initial Therapy — 28 percentage of participants

Primary: Plasma Concentrations of Total Dabigatran, 2h and 12 h (+/-2h) Post Administration of Dabigatran Etexilate — 120.0; 60.4 ng/mL

Primary: Progression Free Survival (PFS) Time From the Date of Randomization to Date of Disease Progression or Death, Whichever Occurred First. — 1.4; 3.3; 5.3 months — p=0.0030

Primary: Achievement of ≥90% Reduction From Baseline PASI Score (PASI90) at Week 12 — 32.6; 73.2; 81.0; 77.1 Percentage of participants — p=<0.0001

Primary: Cumulative Incidence of Grade II to IV Acute GVHD — 53 percentage of incidence

Primary: 6-month Progression-free Survival Rate — 24.5; 46.6 percentage of participants — p=0.005

Primary: Objective Response Rate (ORR) Evaluated Using Response Evaluation Criteria in Solid Tumors (RECIST) — 30; 25 percentage of participants

Primary: Subjects With Serum Cortisol Concentration of ≤18 mcg/dl at 30 Minutes After Adrenocorticotrophic Hormone-challenge (ACTH-challenge) — 0 Subjects

Primary: Disease Control Rate — 13 % of participants with disease control

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 100; 90; 100; 100 percentage of participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 84.6; 96.4; 100.0; 100.0 percentage of participants